8-K Announcements
6Material company update
Jan 28, 2026·SEC
Material company update
Jan 16, 2026·SEC
Material company update
Dec 29, 2025·SEC
Repare Therapeutics Inc.(RPTX)Earnings, Financials & Key Ratios
RPTX•NASDAQ
$2.65
Price updated Jun 20, 2026
AboutRepare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.Show more
- Revenue$53M+4.6%
- EBITDA-$92M+19.8%
- Net Income-$85M+9.7%
- EPS (Diluted)-2.00+10.3%
- Gross Margin74.98%+1.2%
- EBITDA Margin-171.29%+23.4%
- Operating Margin-174.88%+23.1%
- Net Margin-158.37%+13.7%
- ROE-46.63%-22.2%
RPTX Price & Volume
Repare Therapeutics Inc. (RPTX) stock price & volume — 10-year historical chart
Loading chart...
Clinical Milestone Volatility Masks Structural Liquidity Risks
Investment Thesis • Updated 2025Q3
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical milestone funding dependency
"Repare Therapeutics remains a high-risk, clinical-stage biotechnology firm whose valuation is tethered to the success of its SNIPRx platform and the ability to secure future partnership milestones. The company's financial profile is characterized by extreme revenue lumpiness, evidenced by a shift from $52.4M in 2024Q1 revenue to periods of zero revenue, which complicates long-term forecasting. Investors should remain cautious as the erosion of the cash position to $72.8M in 2025Q3, coupled with a massive accumulated deficit of -$461.3M, suggests a high probability of future dilutive financing to sustain ongoing clinical development."
Verdict Logic
the company's reliance on intermittent milestone payments and a declining cash balance of $72.8M in 2025Q3 create significant uncertainty regarding its ability to fund long-term clinical trials without further equity dilution.
RPTX Growth Metrics
Repare Therapeutics Inc. (RPTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years91.62%
TTM-82.16%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM14.1%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM15.5%
Return on Capital
10 Years-44.82%
5 Years-32.07%
3 Years-34.65%
Last Year-51.1%
RPTX Recent Earnings
Repare Therapeutics Inc. (RPTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 5/12 qtrs (56%)
Q2 2026Latest
Mar 2, 2026Metric
Actual
Est
EPS
$0.67-131.0%
$0.29
Rev
—
$3M
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.08+121.6%
$0.35
Rev
$12M+364.8%
$3M
Q3 2025
Aug 8, 2025Metric
Actual
Est
EPS
$0.39+30.4%
$0.56
Rev
$250,000-85.0%
$2M
Q2 2025
May 13, 2025Metric
Actual
Est
EPS
$0.71-9.2%
$0.65
Rev
$5M+200.0%
$2M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 2, 2026 | $0.67vs $0.29-131.0% | —vs $3M |
| Q4 2025 | Nov 14, 2025 | $0.08vs $0.35+121.6% | $12Mvs $3M+364.8% |
| Q3 2025 | Aug 8, 2025 | $0.39vs $0.56+30.4% | $250,000vs $2M-85.0% |
| Q2 2025 | May 13, 2025 | $0.71vs $0.65-9.2% | $5Mvs $2M+200.0% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Repare Therapeutics Inc. (RPTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.65 | $114.24M | -1.33 | 4.58% | -158.37% | -46.63% | — | |
| $182.08 | $38.71B | -30.60 | — | — | -83.22% | — | |
| $1.17 | $62.4M | -0.79 | — | — | -68.98% | — | |
| $115.07 | $6.73B | -28.27 | -79.35% | -1027.25% | -55.42% | — | |
| $108.12 | $8.83B | -29.30 | -16.72% | -612.17% | -25.02% | — | |
| $9.62 | $237.77M | -2.80 | -100% | — | -73.16% | — |
Compare RPTX vs Peers
Repare Therapeutics Inc. (RPTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RPTX SEC Filings & Documents
Repare Therapeutics Inc. (RPTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when RPTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RPTX Frequently Asked Questions
Repare Therapeutics Inc. (RPTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Repare Therapeutics Inc.'s revenue?
Repare Therapeutics Inc. (RPTX) reported $11.9M in revenue for fiscal year 2024.
How fast is Repare Therapeutics Inc. growing?
Repare Therapeutics Inc. (RPTX) grew revenue by 4.6% over the past year. Growth has been modest.
Is RPTX profitable?
Repare Therapeutics Inc. (RPTX) reported a net loss of $72.2M for fiscal year 2024.
Dividend & Returns
What is RPTX's return on equity?
Repare Therapeutics Inc. (RPTX) has a return on equity (ROE) of -46.6%. Negative ROE indicates the company is unprofitable.
What is Repare Therapeutics Inc.'s free cash flow?
Repare Therapeutics Inc. (RPTX) had negative free cash flow of $70.1M in fiscal year 2024, likely due to heavy capital investments.